Podocytopathy in diabetes: a metabolic and endocrine disorder
about
Roles of the (pro)renin receptor in the kidneyBlocking αVβ3 integrin ligand occupancy inhibits the progression of albuminuria in diabetic rats.Messenger RNA levels of podocyte-associated proteins in subjects with different degrees of glucose tolerance with or without nephropathyInsulin signaling: implications for podocyte biology in diabetic kidney disease.Combination of Tripterygium wilfordii Hook F and angiotensin receptor blocker synergistically reduces excretion of urinary podocytes in patients with type 2 diabetic kidney disease.Cardiac and renal function in patients with type 2 diabetes who have chronic kidney disease: potential effects of bardoxolone methyl.Steroid-responsive nephrotic syndrome and bilateral renal artery stenosis: a possible role for Angiotensin-mediated podocyte injury.Exosomes secreted by human urine-derived stem cells could prevent kidney complications from type I diabetes in rats.Role of renal TRP channels in physiology and pathologyCyclodextrin protects podocytes in diabetic kidney disease.Albuminuria according to status of autoimmunity and insulin sensitivity among youth with type 1 and type 2 diabetesShort-term changes after a weight reduction intervention in advanced diabetic nephropathy.Wnt/β-Catenin Signaling Mediated-UCH-L1 Expression in Podocytes of Diabetic Nephropathy.Diabetic nephropathy: Is it time yet for routine kidney biopsy?New Insights into the PPAR γ Agonists for the Treatment of Diabetic Nephropathy.Role of protein kinase C in podocytes and development of glomerular damage in diabetic nephropathy.CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease.CTGF mediates high-glucose induced epithelial-mesenchymal transition through activation of β-catenin in podocytes.Critical role of serum response factor in podocyte epithelial-mesenchymal transition of diabetic nephropathy.Rethinking glomerular basement membrane thickening in diabetic nephropathy: adaptive or pathogenic?Methylglyoxal in Metabolic Disorders: Facts, Myths, and Promises.CIN85 Deficiency Prevents Nephrin Endocytosis and Proteinuria in Diabetes.Spironolactone promotes autophagy via inhibiting PI3K/AKT/mTOR signalling pathway and reduce adhesive capacity damage in podocytes under mechanical stress.Protection of CTGF Antibody Against Diabetic Nephropathy in Mice Via Reducing Glomerular β-Catenin Expression and Podocyte Epithelial-Mesenchymal Transition.Metformin Ameliorates Podocyte Damage by Restoring Renal Tissue Podocalyxin Expression in Type 2 Diabetic RatsDeficient Insulin-mediated Upregulation of the Equilibrative Nucleoside Transporter 2 Contributes to Chronically Increased Adenosine in Diabetic Glomerulopathy.Bisphenol-A induces podocytopathy with proteinuria in mice.Gremlin aggravates hyperglycemia-induced podocyte injury by a TGFβ/smad dependent signaling pathway.3,4-DGE is cytotoxic and decreases HSP27/HSPB1 in podocytes.Close relations between podocyte injuries and membranous proliferative glomerulonephritis in autoimmune murine models.MDM2 is implicated in high-glucose-induced podocyte mitotic catastrophe via Notch1 signalling.The locally activated renin-angiotensin system is involved in albumin permeability in glomerular endothelial cells under high glucose conditions.NMDA receptors participate in the progression of diabetic kidney disease by decreasing Cdc42-GTP activation in podocytes.N-acetylcysteine ameliorates acute kidney injury but not glomerular hemorrhage in an animal model of warfarin-related nephropathy.Chrysin ameliorates podocyte injury and slit diaphragm protein loss via inhibition of the PERK-eIF2α-ATF-CHOP pathway in diabetic mice.Glucose Transporters in Diabetic Kidney Disease-Friends or Foes?
P2860
Q27026784-6633BA14-A7CD-417A-BCC1-F13D1DBF7064Q34441673-1A4B7843-0A66-43D1-ABD6-4C7FCB8C0EE1Q35011234-E4EA4239-5629-461C-A14F-503EB13D96C5Q35285585-B91B54D0-31DD-4DAA-B747-0F7CE0229A74Q35613785-E866667A-E356-4A33-AC5C-D889D21BA71EQ36083217-17F7805F-05C7-4956-BB2C-D68F523611D7Q36350102-CD29BAF1-4D17-4C7D-85C4-B117CAFFD53EQ36553203-0005CAC5-3C82-4CC3-BD87-FC790B15DC05Q36703547-DE6E0F08-8EBC-4C69-889D-8D6AE9108E74Q37251166-4E96C386-4234-4107-8552-0A23CDC0B425Q37277951-E9AE8332-0BD7-4FD4-B9CF-5C36679C4E19Q37280851-3084F105-F7C3-4B9A-8D75-46150231C0A5Q37286286-D93A1498-03AD-442D-88BA-C246D09A7732Q37417746-375A992E-83B1-4C74-A466-F1EDB876F081Q37590946-40970DA8-900D-4804-8AC9-DDF199B2628BQ38270180-7371F012-C40D-48ED-B383-4F73758D46A7Q38593433-5E709ADF-497C-46DB-BEA5-FC4FF012BEAFQ38785733-12386262-BFCF-4C3F-98F0-E671ACFA33B6Q38832336-23C3D3BF-6428-48CF-BAC0-6C8EA7347180Q38942962-BAFA0E58-C50B-4B0D-8CBC-99FBF0FACF52Q38956425-5B8E3D1A-E6D5-471F-8C08-6C13B12073B2Q39517180-C65562A4-8191-448D-97B1-FFD01307FE2EQ39809455-BB0B7D83-1421-49B5-8606-F6B4B1A68D3BQ40267201-AB6E651E-9238-479A-A28F-3A54301D031EQ41108451-C6AABC87-3CD7-41D2-84C0-2E54C129B4E2Q41529248-0CE87CC1-5018-4672-A9E1-E55DBA13513EQ42705734-DD6DA03F-C477-4AB6-ADCA-6F0B87323A90Q44654330-D58173BA-6473-4E6E-A8BF-35A98B75D797Q44979188-492639FB-5544-444E-B9C3-10E93478C299Q46345674-CB93A364-9DE3-4550-B0A6-3E6D21BB303CQ47117632-4D44A163-3088-4C65-A6A4-99790BF25503Q48649007-10A2E0E7-25A2-4D5D-BD12-BCA6BCADC8AFQ48659334-DB789FB6-5206-45E6-8E24-F52BF1610B0CQ50492507-3A7036AB-3C9E-4109-BC37-EEF199E6AEB3Q51002474-2EC0E2B3-E912-457D-AF3C-1893614DA98AQ52568352-3AD863A9-672B-46E8-9D84-E8E69BC2F923
P2860
Podocytopathy in diabetes: a metabolic and endocrine disorder
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Podocytopathy in diabetes: a metabolic and endocrine disorder
@en
Podocytopathy in diabetes: a metabolic and endocrine disorder.
@nl
type
label
Podocytopathy in diabetes: a metabolic and endocrine disorder
@en
Podocytopathy in diabetes: a metabolic and endocrine disorder.
@nl
prefLabel
Podocytopathy in diabetes: a metabolic and endocrine disorder
@en
Podocytopathy in diabetes: a metabolic and endocrine disorder.
@nl
P2860
P1476
Podocytopathy in diabetes: a metabolic and endocrine disorder
@en
P2093
Alessia Fornoni
Ana Diez-Sampedro
P2860
P304
P356
10.1053/J.AJKD.2011.03.035
P50
P577
2011-06-29T00:00:00Z